Mitsubishi Tanabe Pharma America
Mitsubishi Tanabe Pharma America, a subsidiary of Mitsubishi Tanabe Pharma Corporation, is headquartered in the United States and operates primarily in the biopharmaceutical industry. Founded in 2008, the company has established itself as a key player in the development of innovative therapies, particularly in the areas of neurology, immunology, and rare diseases. With a strong focus on research and development, Mitsubishi Tanabe Pharma America offers unique products that address unmet medical needs, including treatments for conditions such as multiple sclerosis and amyotrophic lateral sclerosis (ALS). The company’s commitment to advancing healthcare solutions has positioned it as a notable entity within the pharmaceutical landscape, recognised for its contributions to patient care and therapeutic advancements.
DitchCarbon Score
How does Mitsubishi Tanabe Pharma America's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mitsubishi Tanabe Pharma America's score of 3 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Mitsubishi Tanabe Pharma America's reported carbon emissions
Mitsubishi Tanabe Pharma America, headquartered in the US, currently does not provide specific carbon emissions data or reduction targets. Without available figures, it is challenging to assess their carbon footprint or climate commitments in detail. However, the company is likely to be engaged in industry-standard practices aimed at reducing environmental impact, aligning with broader pharmaceutical sector initiatives to enhance sustainability. As the industry increasingly focuses on climate action, Mitsubishi Tanabe Pharma America may be expected to adopt strategies that contribute to reducing greenhouse gas emissions in the future.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Mitsubishi Tanabe Pharma America is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
